Since the model of TIDE was developed and validated based on melanoma patients treated with first-line anti-PD1 or anti-CTLA4, TMEscore can be used as a biomarker to predict the tumor response to anti-PD1 or anti-CTLA4, but whether TMEscore can predict the tumor response to other ICIs remains uncertain. The gene discussed is CTLA4; the disease is melanoma.